Targeting nucleotide excision repair in combination cancer therapy

联合癌症治疗中的靶向核苷酸切除修复

基本信息

项目摘要

Abstract First line treatment of ovarian cancer includes combination therapy with a platinum drug (Pt), either cisplatin or carboplatin (1). A major impediment to the successful treatment of epithelial ovarian cancer (EOC) is resistance to Pt-based chemotherapeutic agents (3). Even in EOCs that initially respond to treatment, most will recur and will be Pt resistant; with an extremely poor prognosis as second line therapies are largely ineffective. The difficulties in providing effective treatment of EOC highlights the importance of tailoring therapies based on the biology of the individual disease. Recent advances in our understanding of the homologous recombination (HR)/BRCA pathway in breast and ovarian cancer (4;5) and the common alteration of HR in these cancers has led to targeting poly-ADP-ribose polymerase (PARP) by exploiting the concept of synthetic lethality. While PARP inhibitors have had some success in single agent studies in BRCA mutant cancers, combination of PARP inhibitors with Pt therapy has been considerably less effective. Pt agents impart their therapeutic effect by the formation of Pt-DNA adducts, which block DNA replication and transcription. Repair of Pt-DNA adducts reduces the efficacy of platinum-based treatment and contributes to cellular resistance. Importantly, repair of Pt-DNA damage is catalyzed by the PARP-independent pathways, nucleotide excision repair (NER) and homologous recombination repair (HRR). Thus, in HRR deficient cancers, targeting NER would be expected to have a significant impact on sensitivity to Pt therapy. Germ line mutations in BRCA1 or 2 predispose women to hereditary breast and ovarian cancer which are HRR deficient. Therefore we will address the hypothesis that synthetic lethal interactions can be exploited targeting the NER pathway with small molecules in HRR deficient cancers and, when combined with cisplatin will provide increased efficacy with minimal toxicity. Cisplatin treatment, in combination with an NER inhibitor, will differentially alter the repair capacity of different cells dependent on their HRR status. Non-cancerous, HRR proficient cells can repair or tolerate the cisplatin damage via HRR and thus will have reduced toxicity compared to the HRR deficient cancer cells which are unable to repair the cisplatin damage via either pathway. To address our hypothesis we will employ our recently discovered NER inhibitors targeting the xeroderma pigmentosum group A (XPA) protein (6) and replication protein A (RPA) (7-9) in two specific aims. Aim 1 will develop and characterize novel inhibitors of the XPA protein and assess efficacy in combination with cisplatin in cell culture models of HRR proficient and deficient human ovarian and breast cancers. We will then determine the impact of XPA inhibition in combination with cisplatin therapy on cytotoxicity, DNA damage signaling and repair of cisplatin-DNA damage in cell culture and xenograft models of breast and ovarian cancer. In aim 2 we will determine the mechanism by which small molecules targeting the RPA protein inhibit the RPA-DNA binding interaction, achieve single agent activity and synergize with cisplatin and etoposide in BRCA1 deficient cancers. Our previous data identified two classes of RPA inhibitors, both of which decrease
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN J. TURCHI其他文献

JOHN J. TURCHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN J. TURCHI', 18)}}的其他基金

Novel DNA damage response therapeutics targeting replication protein A
针对复制蛋白 A 的新型 DNA 损伤反应疗法
  • 批准号:
    10317276
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Novel DNA damage response therapeutics targeting replication protein A
针对复制蛋白 A 的新型 DNA 损伤反应疗法
  • 批准号:
    10432115
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Novel DNA damage response therapeutics targeting replication protein A
针对复制蛋白 A 的新型 DNA 损伤反应疗法
  • 批准号:
    10653707
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
针对治疗的基因组稳定性和维持的新型药物的开发
  • 批准号:
    8649744
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:
Targeting nucleotide excision repair in combination cancer therapy
联合癌症治疗中的靶向核苷酸切除修复
  • 批准号:
    8898026
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:
Targeting nucleotide excision repair in combination cancer therapy
联合癌症治疗中的靶向核苷酸切除修复
  • 批准号:
    8743197
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:
Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
针对治疗的基因组稳定性和维持的新型药物的开发
  • 批准号:
    8201446
  • 财政年份:
    2012
  • 资助金额:
    $ 32.37万
  • 项目类别:
Development of methodologies for the analysis of DNA repair capacity to predict t
开发分析 DNA 修复能力以预测 t 的方法
  • 批准号:
    7434231
  • 财政年份:
    2008
  • 资助金额:
    $ 32.37万
  • 项目类别:
Development of methodologies for the analysis of DNA repair capacity to predict t
开发分析 DNA 修复能力以预测 t 的方法
  • 批准号:
    7682236
  • 财政年份:
    2008
  • 资助金额:
    $ 32.37万
  • 项目类别:
RECOGNITION AND REPAIR OF CISPLATIN DNA DAMAGE
顺铂 DNA 损伤的识别和修复
  • 批准号:
    6633491
  • 财政年份:
    2000
  • 资助金额:
    $ 32.37万
  • 项目类别:

相似海外基金

Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8077875
  • 财政年份:
    2010
  • 资助金额:
    $ 32.37万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    7866149
  • 财政年份:
    2010
  • 资助金额:
    $ 32.37万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8589822
  • 财政年份:
    2010
  • 资助金额:
    $ 32.37万
  • 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
  • 批准号:
    8305149
  • 财政年份:
    2010
  • 资助金额:
    $ 32.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了